- Author: Donald A Dibbern, Jr, MD; Chief Editor: Michael A Kaliner, MD more...
Wiskott-Aldrich syndrome (WAS) is a condition with variable expression, but commonly includes immunoglobulin M (IgM) deficiency. WAS always causes persistent thrombocytopenia and, in its complete form, also causes small platelets, atopy, cellular and humoral immunodeficiency, and an increased risk of autoimmune disease and hematologic malignancy. In one study of 154 patients with WAS, only 30% had a classic presentation with thrombocytopenia, small platelets, eczema, and immunodeficiency; although 84% had clinical signs and symptoms of thrombocytopenia, 20% had only hematologic abnormalities, 5% had only infectious manifestations, and none had eczema exclusively. WAS is an X-linked recessive genetic condition; therefore, this disorder is found almost exclusively in boys. WAS has been the focus of intense molecular biology research, which recently led to the isolation of the affected gene product.
WAS results from an X-linked genetic defect in a protein now termed Wiskott-Aldrich syndrome protein (WASp). The gene resides on Xp11.22-23, and its expression is limited to cells of hematopoietic lineage. The exact function of WASp is not fully elucidated, but it seems to function as a bridge between signaling and movement of the actin filaments in the cytoskeleton. Researchers identified many different mutations that interfere with the protein binding to Cdc42 and Rac GTPases, among other binding partners, most of which are involved in regulation of the actin cytoskeleton of lymphocytes. This ultrastructural component of cellular architecture is involved fundamentally in intracellular and cell substrate interactions and signaling via its role in cell morphology and movement. The actin cytoskeleton is responsible for cellular functions such as growth, endocytosis, exocytosis, and cytokinesis.
Researchers propose several models of actin assembly; this topic is an extremely active area of cell biology research. Actin filament growth occurs by rapid monomer addition (polymerization) to the barbed leading end of a nucleated site. Nucleation, the rate-limiting step, is stimulated by a complex of actin-related protein Arp2/3 and WASp. Cdc42 GTPase also interacts with WASp to increase this nucleation. Next, gelsolin (activated by Ca++) severs actin filaments to create barbed ends, but then must be uncapped from the filament by phosphatidylinositol 4,5-bisphosphonate and Rac to proceed with polymerization. WASp also interacts with Rac and, thus, is involved in regulation of this process at multiple interrelated sites.
WAS neutrophils have been reported to manifest abnormal NAD(P)H autofluorescence, indicating defective intracellular energy flux. Presumably, WASp mutations interfere with the proper signaling and growth of cells of the hematopoietic lineage, resulting in the platelet and immune defects observed clinically, although the exact mechanisms and defective pathways remain largely unknown.
Recently published research demonstrates that the Cdc42-WASp interaction is necessary for certain chemoattractant-induced T-cell chemotaxis. Further studies have now demonstrated abnormal migration and motility in multiple key cellular components of the immune system (specifically, dendritic cells and neutrophils, as well as both B and T lymphocytes).[7, 8] With regard to WASp-deficient neutrophil adhesion and migration abnormalities, this may be caused by profound defects in clustering beta-2 integrins. Also of note, CD43 (a major T-cell sialoglycoprotein) is located on microvilli; disruption of WASp regulation of cytoskeletal structure may be the cause of the CD43 defects often observed in patients with WAS. WASp may also have a role in transcriptional signaling and regulation of NK cells, independent of its functions in cytoskeletal actin polymerization.
Studies of genotype-phenotype correlation in WAS and closely related conditions, with detailed analyses of WASp expression, have now linked absent WASp expression to classic WAS, mutant WASp expression to X-linked thrombocytopenia, and WASp with missense mutations at the Cdc42-binding site to X-linked neutropenia.[12, 13, 14] Extensive study is also underway to further identify and characterize important WASp-associated proteins, such as WASp-interacting protein (WIP)[15, 16, 17, 18, 19] and several Wiskott-Aldrich syndrome proteins verprolin homologous (WAVE).[20, 21, 22] New research suggests that N-WASp (neural Wiskott-Aldrich syndrome protein), a ubiquitously expressed homologue of WASp, may have some redundancy with WASp itself.
Incidence is 4 cases per 1 million live male births, which remained relatively unchanged from 1947-1976.
A study from Switzerland reported the incidence of WAS is 4.1 cases per 1 million live births. The same study also examined the prevalence of WAS in several national registries (ie, Italy, Japan, Switzerland, Sweden) and found that this condition occurred in 2-8.8% of patients with primary immunodeficiencies, although this statistic is subject to ascertainment bias. A similar range has been documented in a national registry in Ireland, as well.
See the list below:
The cause of death is largely infections or bleeding, but, in one series, 12% of patients developed malignancies, primarily lymphoreticular tumors, and leukemia. In that series, the relative risk of malignancy was more than 100-fold that of normal and the risk increased with age.  Another study showed similar results, with the reported cause of death among patients who did not receive bone marrow transplants being infection (44%), bleeding (23%), or malignancy (26%). 
With aggressive care (eg, splenectomy), longer survival is possible. [27, 28] Bone marrow transplant can be curative.  Survival rates after stem cell transplant have continued to increase, particularly after more recent emphasis on performing these procedures as soon as possible after diagnosis. [29, 30]
Outcomes of hematopoietic cell transplantation have especially improved since 2000. 
See the list below:
One large series of 301 confirmed and probable cases of WAS from 149 families reported that 8 families were black and 4 families were Chicano. Of the 40 families whose ancestry was traced outside North America, 38 emigrated from Europe. 
See the list below:
WAS is an X-linked recessive genetic disorder. The abnormal gene is relatively rare, and affected individuals often do not survive childhood.
WAS occurs almost exclusively in males, although it is also reported in females. One report of WAS in an 8-year-old girl found a WASp gene mutation on her paternal X chromosome associated with nonrandom inactivation of her maternal X chromosome.  Other closely related genetic abnormalities (such as WIP deficiency) have also been reported in females, with clinical features similar to WAS. 
See the list below:
WAS is a severe congenital immunodeficiency; therefore, it occurs primarily in children. However, 2 large case series reported patients in their fourth decade of life. [24, 2]
Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999 Dec. 93(3):190-7. [Medline].
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994 Dec. 125(6 Pt 1):876-85. [Medline].
Snapper SB, Rosen FS. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu Rev Immunol. 1999. 17:905-29. [Medline].
Kwan SP, Hagemann TL, Radtke BE, et al. Identification of mutations in the Wiskott-Aldrich syndrome gene and characterization of a polymorphic dinucleotide repeat at DXS6940, adjacent to the disease gene. Proc Natl Acad Sci U S A. 1995 May 9. 92(10):4706-10. [Medline].
Yin HL, Stull JT. Proteins that regulate dynamic actin remodeling in response to membrane signaling minireview series. J Biol Chem. 1999 Nov 12. 274(46):32529-30. [Medline].
Haddad E, Zugaza JL, Louache F, et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T- lymphocyte chemotaxis. Blood. 2001 Jan 1. 97(1):33-8. [Medline].
Snapper SB, Meelu P, Nguyen D, et al. WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. J Leukoc Biol. 2005 Mar 17. Epub:[Medline].
Westerberg L, Larsson M, Hardy SJ, et al. Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood. 2005 Feb 1. 105(3):1144-52.
Zhang H, Schaff UY, Green CE, Chen H, Sarantos MR, Hu Y. Impaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils. Immunity. 2006 Aug. 25(2):285-95. [Medline].
Remold-O'Donnell E, Rosen FS. Sialophorin (CD43) and the Wiskott-Aldrich syndrome. Immunodefic Rev. 1990. 2(2):151-74. [Medline].
Huang W, Ochs HD, Dupont B, et al. The Wiskott-Aldrich syndrome protein regulates nuclear translocation of NFAT2 and NF-kappaB (RelA) independently of its role in filamentous actin polymerization and actin cytoskeletal rearrangement. J Immunol. 2005 Mar 1. 174(5):2602-11. [Medline].
Ochs HD, Notarangelo LD. Structure and function of the Wiskott-Aldrich syndrome protein. Curr Opin Hematol. 2005 Jul. 12(4):284-91. [Medline].
Notarangelo LD, Notarangelo LD, Ochs HD. WASP and the phenotypic range associated with deficiency. Curr Opin Allergy Clin Immunol. 2005 Dec. 5(6):485-90. [Medline].
Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006 Apr. 117(4):725-38; quiz 739. [Medline].
Anton IM, Jones GE. WIP: a multifunctional protein involved in actin cytoskeleton regulation. Eur J Cell Biol. 2006 Apr. 85(3-4):295-304. [Medline].
de la Fuente MA, Sasahara Y, Calamito M, et al. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A. 2007 Jan 16. 104(3):926-31. [Medline].
Konno A, Kirby M, Anderson SA, Schwartzberg PL, Candotti F. The expression of Wiskott-Aldrich syndrome protein (WASP) is dependent on WASP-interacting protein (WIP). Int Immunol. 2007 Feb. 19(2):185-92. [Medline].
Calle Y, Anton IM, Thrasher AJ, Jones GE. WASP and WIP regulate podosomes in migrating leukocytes. J Microsc. 2008 Sep. 231(3):494-505. [Medline].
Ramesh N, Geha R. Recent advances in the biology of WASP and WIP. Immunol Res. 2008 Nov 19. [Medline].
Soderling SH, Scott JD. WAVE signalling: from biochemistry to biology. Biochem Soc Trans. 2006 Feb. 34(Pt 1):73-6. [Medline].
Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007 Jan. 8(1):37-48. [Medline].
H Pauker M, Reicher B, Joseph N, Wortzel I, Jakubowicz S, Noy E, et al. WASp Family Verprolin-Homologous Protein-2 (WAVE2) and Wiskott-Aldrich Syndrome Protein (WASp) Engage in Distinct Downstream Signaling Interactions at the T Cell Antigen Receptor Site. J Biol Chem. 2014 Oct 23. [Medline].
Westerberg LS, Dahlberg C, Baptista M, et al. Wiskott-Aldrich syndrome protein (WASP) and N-WASP are critical for peripheral B cell development and function. Blood. 2012 Mar 12. [Medline].
Perry GS 3d, Spector BD, Schuman LM, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892- 1979). J Pediatr. 1980 Jul. 97(1):72-8. [Medline].
Ryser O, Morell A, Hitzig WH. Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children. J Clin Immunol. 1988 Nov. 8(6):479-85. [Medline].
Abuzakouk M, Feighery C. Primary Immunodeficiency Disorders in the Republic of Ireland: First Report of the National Registry in Children and Adults. J Clin Immunol. 2005 Jan. 25(1):73-77. [Medline].
Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood. 1993 Nov 15. 82(10):2961-6. [Medline].
Kobayashi R, Ariga T, Nonoyama S, Kanegane H, Tsuchiya S, Morio T. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol. 2006 Nov. 135(3):362-6. [Medline].
Pai SY, DeMartiis D, Forino C, Cavagnini S, Lanfranchi A, Giliani S. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant. 2006 Nov. 38(10):671-9. [Medline].
Shin CR, Kim MO, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant. 2012 Mar 19. [Medline].
Parolini O, Ressmann G, Haas OA, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med. 1998 Jan 29. 338(5):291-5. [Medline].
Peacocke M, Siminovitch KA. Wiskott-Aldrich syndrome: new molecular and biochemical insights. J Am Acad Dermatol. 1992 Oct. 27(4):507-19. [Medline].
Senapati J, Devasia AJ, David S, Manipadam MT, Nair S, Jayandharan GR, et al. Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature. Indian J Hematol Blood Transfus. 2014 Sep. 30:309-13. [Medline]. [Full Text].
Ochs HD. Mutations of the Wiskott-Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes. Immunol Res. 2008 Dec 11. [Medline].
Schwaber J, Rosen FS. X chromosome linked immunodeficiency. Immunodefic Rev. 1990. 2(3):233-51. [Medline].
Ochs HD, Slichter SJ, Harker LA, et al. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980 Feb. 55(2):243-52. [Medline].
Schwartz M, Mibashan RS, Nicolaides KH, et al. First-trimester diagnosis of Wiskott-Aldrich syndrome by DNA markers [letter]. Lancet. 1989 Dec 9. 2(8676):1405. [Medline].
Kenney DM. Wiskott-Aldrich syndrome and related X-linked thrombocytopenia. Curr Opin Pediatr. 1990. 2:931-4.
Buckley RH. Advances in the correction of immunodeficiency by bone marrow transplantation. Pediatr Ann. 1987 May. 16(5):412-3, 416-21. [Medline].
Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001 Mar 15. 97(6):1598-603. [Medline].
Knutsen AP, Steffen M, Wassmer K, et al. Umbilical cord blood transplantation in Wiskott Aldrich syndrome. J Pediatr. 2003 May. 142(5):519-23. [Medline].
Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2008 Jan. 15(1 Suppl):84-90. [Medline].
Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med. 1978 Apr 27. 298(17):921-7. [Medline].
Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct. 8(5):390-5. [Medline].
Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther. 2008 Feb. 8(2):181-90. [Medline].
Frecha C, Toscano MG, Costa C, Saez-Lara MJ, Cosset FL, Verhoeyen E. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis. Gene Ther. 2008 Jun. 15(12):930-41. [Medline].
Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S, et al. Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskott-Aldrich Syndrome in Preclinical Models. Mol Ther. 2009 Mar 3. [Medline].
Bosticardo M, Ferrua F, Cavazzana M, Aiuti A. Gene therapy for wiskott-Aldrich syndrome. Curr Gene Ther. 2014. 14(6):413-21. [Medline].
Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical Safety and Efficacy of Human CD34(+) Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. Mol Ther. 2012 Feb 28. [Medline].
Galy A, Thrasher AJ. Gene therapy for the Wiskott-Aldrich syndrome. Curr Opin Allergy Clin Immunol. 2011 Dec. 11(6):545-50. [Medline].
Astrakhan A, Sather BD, Ryu BY, et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich Syndrome. Blood. 2012 Mar 19. [Medline].
Hacein-Bey Abina S, Gaspar HB, Blondeau J, Caccavelli L, Charrier S, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015 Apr 21. 313 (15):1550-63. [Medline].
Litzman J, Jones A, Hann I, et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child. 1996 Nov. 75(5):436-9. [Medline].
Lum LG, Tubergen DG, Corash L, Blaese RM. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med. 1980 Apr 17. 302(16):892-6. [Medline].
Akman IO, Ostrov BE, Neudorf S. Autoimmune manifestations of the Wiskott-Aldrich syndrome. Semin Arthritis Rheum. 1998 Feb. 27(4):218-25. [Medline].
Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003 May. 111(5 Pt 1):e622-7. [Medline].
Buckley RH. Primary Immunodeficiency Diseases. Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, eds. Allergy: Principles and Practice. 5th ed. St. Louis, Mo: Mosby-Year Book; 1998. Vol 2: 713-34.
Winkelstein JA, Fearon E. Carrier detection of the X-linked primary immunodeficiency diseases using X-chromosome inactivation analysis. J Allergy Clin Immunol. 1990 Jun. 85(6):1090-7. [Medline].
Conley ME, Saragoussi D, Notarangelo L, et al. An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol. 2003 Dec. 109(3):272-7. [Medline].
Friedrich W, Schutz C, Schulz A, Benninghoff U, Honig M. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors. Immunol Res. 2008 Oct 10. [Medline].
Grabenstein JD. Immune Globulin Intravenous (Human). ImmunoFacts: Vaccines & Immunologic Drugs. Conshohocken, Pa: Wolters Kluwer Health (Facts and Comparisons); 1999. 212-24b.
Guill MF, Brown DA, Ochs HD, et al. IgM deficiency: clinical spectrum and immunologic assessment. Ann Allergy. 1989 Jun. 62(6):547-52. [Medline].
Hobbs JR, Milner RD, Watt PJ. Gamma-M deficiency predisposing to meningococcal septicaemia. Br Med J. 1967 Dec 9. 4(579):583-6. [Medline].
National Institutes of Health Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA. 1990 Dec 26. 264(24):3189-93. [Medline].
Park JY, Shcherbina A, Rosen FS, et al. Phenotypic perturbation of B cells in the Wiskott-Aldrich syndrome. Clin Exp Immunol. 2005 Feb. 139(2):297-305. [Medline].
Sorensen RU, Tomford JW, Gyves MT, et al. Use of intravenous immune globulin in pregnant women with common variable hypogammaglobulinemia. Am J Med. 1984 Mar 30. 76(3A):73-7. [Medline].
Taha S, Kindzelskii AL, Petty HR. Neutrophils Metabolic Oscillations in Wiskott-Aldrich Syndrome. J Allergy Clin Immunol. 2000. 105 (part 1 of 2):S217.
Yocum MW, Strong DM, Chusid MJ, Lakin JD. Selective immunoglobulin M (IgM) deficiency in two immunodeficient adults with recurrent staphylococcal pyoderma. Am J Med. 1976 Apr. 60(4):486-94. [Medline].